Evidence-based Recommendations for Monitoring Safety of Second Generation Antipsychotics in Children and Youth

Overview

Journal J Can Acad Child Adolesc Psychiatry

Date 2011 Aug 2

PMID 21804853

Citations 39

Authors

Tamara Pringsheim

Constadina Panagiotopoulos

Jana Davidson

Josephine Ho

Affiliations

Soon will be listed here.

Abstract

Background: The use of antipsychotics, especially second generation antipsychotics (SGAs), for children with mental health disorders in Canada has increased dramatically over the past five years. These medications have the potential to cause major metabolic and neurological complications with chronic use.

Objective: Our objective was to synthesize the evidence for specific metabolic and neurological side effects associated with the use of SGAs in children and make evidence-based recommendations for the monitoring of these side effects.

Methods: We performed a systematic review of controlled clinical trials of SGAs in children. Recommendations for monitoring SGA safety were made according to a classification scheme based on the GRADE system. When there was inadequate evidence to make recommendations, recommendations were based on consensus and expert opinion. A multi-disciplinary consensus group reviewed all relevant evidence and came to consensus on recommendations.

Results: Evidence-based recommendations for monitoring SGA safety are provided in the guideline. The strength of recommendations for specific physical examination maneuvers and laboratory tests are provided for each SGA medication at specific time points.

Conclusion: Multiple randomized controlled trials (RCTs) have established the efficacy of many of the SGAs in pediatric mental health disorders. These benefits however do not come without risk; both metabolic and neurological side effects occur in children treated with these SGAs. The risk of weight gain, increased BMI and abnormal lipids appears greatest with olanzapine, followed by clozapine and quetiapine. The risk of neurological side effects of treatment appears greatest with risperidone, olanzapine and aripiprazole. Appropriate monitoring procedures for adverse effects will improve the quality of care of children treated with these medications.

Citing Articles

On the Road to Individualizing Pharmacotherapy for Adolescents and Adults with Schizophrenia - Results from an Expert Consensus Following the Delphi Method.

Guinart D, Fagiolini A, Fusar-Poli P, Giordano G, Leucht S, Moreno C Neuropsychiatr Dis Treat. 2024; 20:1139-1152.

PMID: 38812809 PMC: 11133879. DOI: 10.2147/NDT.S456163.

Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.

Koch M, Carlson H, Kazimi M, Correll C J Am Acad Child Adolesc Psychiatry. 2023; 62(9):1021-1050.

PMID: 36931560 PMC: 10502189. DOI: 10.1016/j.jaac.2023.03.007.

Geographic variation and sociodemographic correlates of prescription psychotropic drug use among children and youth in Ontario, Canada: a population-based study.

Antoniou T, McCormack D, Kitchen S, Pajer K, Gardner W, Lunsky Y BMC Public Health. 2023; 23(1):85.

PMID: 36631810 PMC: 9832754. DOI: 10.1186/s12889-022-14677-6.

Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice.

Egberts K, Gerlach M, Correll C, Plener P, Malzahn U, Heuschmann P Pharmacopsychiatry. 2022; 55(5):255-265.

PMID: 35130562 PMC: 9458344. DOI: 10.1055/a-1716-1856.

Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) With Language Impairment Accompanied by Developmental Disability Caused by Forkhead Box Protein 1 (FOXP1) Exon Deletion: A Case Report.

Alenezi S, Alyahya A, Aldhalaan H Cureus. 2022; 13(12):e20595.

PMID: 35103171 PMC: 8782629. DOI: 10.7759/cureus.20595.

References

Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A . Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002; 41(9):1026-36. DOI: 10.1097/00004583-200209000-00002. View

Reyes M, Croonenberghs J, Augustyns I, Eerdekens M . Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol. 2006; 16(3):260-72. DOI: 10.1089/cap.2006.16.260. View

DelBello M, Adler C, Whitsel R, Stanford K, Strakowski S . A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry. 2007; 68(5):789-95. DOI: 10.4088/jcp.v68n0520. View

Biederman J, Mick E, Spencer T, Dougherty M, Aleardi M, Wozniak J . A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Bipolar Disord. 2007; 9(8):888-94. DOI: 10.1111/j.1399-5618.2007.00450.x. View

Aman M, de Smedt G, Derivan A, Lyons B, Findling R . Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002; 159(8):1337-46. DOI: 10.1176/appi.ajp.159.8.1337. View

Milin R, Simeon J, Batth S, Thatte S, Dare G, Walker S . An open trial of olanzapine in children and adolescents with Asperger Disorder. J Clin Psychopharmacol. 2006; 26(1):90-2. DOI: 10.1097/01.jcp.0000196114.93376.86. View

Stigler K, Diener J, Kohn A, Li L, Erickson C, Posey D . Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol. 2009; 19(3):265-74. PMC: 2872206. DOI: 10.1089/cap.2008.093. View

DelBello M, Schwiers M, Lee Rosenberg H, Strakowski S . A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002; 41(10):1216-23. DOI: 10.1097/00004583-200210000-00011. View

Shaw P, Sporn A, Gogtay N, Overman G, Greenstein D, Gochman P . Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006; 63(7):721-30. DOI: 10.1001/archpsyc.63.7.721. View

10.

Hollander E, Wasserman S, Swanson E, Chaplin W, Schapiro M, Zagursky K . A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006; 16(5):541-8. DOI: 10.1089/cap.2006.16.541. View

11.

Tramontina S, Zeni C, Ketzer C, Pheula G, Narvaez J, Rohde L . Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. 2009; 70(5):756-64. DOI: 10.4088/JCP.08m04726. View

12.

Sikich L, Frazier J, McClellan J, Findling R, Vitiello B, Ritz L . Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008; 165(11):1420-31. DOI: 10.1176/appi.ajp.2008.08050756. View

13.

Croonenberghs J, Fegert J, Findling R, de Smedt G, Van Dongen S . Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry. 2004; 44(1):64-72. DOI: 10.1097/01.chi.0000145805.24274.09. View

14.

Haas M, Unis A, Armenteros J, Copenhaver M, Quiroz J, Kushner S . A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009; 19(6):611-21. DOI: 10.1089/cap.2008.0144. View

15.

Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G . Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002; 41(3):337-43. DOI: 10.1097/00004583-200203000-00014. View

16.

Koller E, Weber J, Doraiswamy P, Schneider B . A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry. 2004; 65(6):857-63. DOI: 10.4088/jcp.v65n0619. View

17.

Gogtay N, Sporn A, Alfaro C, Mulqueen A, Rapoport J . Clozapine-induced akathisia in children with schizophrenia. J Child Adolesc Psychopharmacol. 2003; 12(4):347-9. DOI: 10.1089/104454602762599899. View

18.

Sikich L, Hamer R, Bashford R, Sheitman B, Lieberman J . A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2003; 29(1):133-45. DOI: 10.1038/sj.npp.1300327. View

19.

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

20.

Haas M, DelBello M, Pandina G, Kushner S, Van Hove I, Augustyns I . Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009; 11(7):687-700. DOI: 10.1111/j.1399-5618.2009.00750.x. View